분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-12-12 11:30:57 , Hit : 1143
 FDA approves 9-valent HPV vaccine for certain cancers

FDA approvals
  
December 10, 2014
  

The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of anal, cervical, vaginal and vulvar cancers.

  

See Also
HPV vaccination rates among girls lowest in states with ...
Few physicians routinely recommend HPV vaccine to boys ...
Effective implementation of nine-valent HPV vaccination could ...
  

The recombinant HPV 9-valent vaccine (Gardasil 9, Merck) covers nine HPV types, which is five more than the quadrivalent HPV vaccine (Gardasil).

The vaccine is indicated for females aged 9 to 26 years and males aged 9 to 15 years, and for cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58 and for the prevention of genital warts caused by HPV types 6 or 11.

The additional five types of HPV that Gardasil 9 adds protection against (31, 33, 45, 52 and 58) are the cause of approximately 20% of cervical cancers and are not covered in previous FDA-approved HPV vaccines.

“Vaccination is a critical public health measure for lowering the risk of most cervical, genital and anal cancers caused by HPV,” Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said in a press release. “The approval of Gardasil 9 provides broader protection against HPV-related cancers.”

Karen Midthun, MD
Karen Midthun

A randomized controlled international study was conducted using a cohort of approximately 14,000 females (median age, 21 years) who tested negative for vaccine HPV types at the start of the study. Patients were randomly assigned Gardasil 9 or Gardasil.

Gardasil 9 was found to be 97% effective in preventing cervical, vulvar and vaginal cancers caused by the additional HPV types.

In addition, Gardasil 9 was equally as effective as Gardasil in the prevention in the four other HPV types (6, 11, 16 and 18).

There is a low incidence of anal cancer caused by the five additional HPV types. As such, the preventive analysis is based on Gardasil’s demonstrated effectiveness of 78% and additional data on antibodies in males and females who received Gardasil 9.

For children aged 9 to 15 years, the effectiveness of Gardasil 9 was identified in studies that measured antibody response to the vaccine. The study group consisted of approximately 1,200 males and 2,800 females. Their response was similar to participants aged 16 to 26 years. Therefore, the vaccine is expected to have similar effectiveness in the younger age group.

Gardasil 9 is administered as three separate vaccinations, with the initial dose followed by additional vaccinations 2 to 6 months later.

Indications are that patients vaccinated before becoming infected with the HPV strains would benefit the most from Gardasil 9.

The safety of the agent was evaluated in approximately 13,000 males and females, and the most common adverse effects were pain at the injection site, swelling, redness and headaches.







827   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1669
826   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1077
825   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1240
824   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1095
  FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1143
822   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1721
821   Y 염색체 상실을 초래할 수 있는 흡연  이성욱 2014/12/10 1344
820   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1272
819   혈우병 환자들에게 안전성과 효과를 입증한 유전자 요법  이성욱 2014/11/27 1616
818   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1284
817   AMD를 치료하는데 사용될 수 있는 HIV/AIDS 약물들  이성욱 2014/11/26 1394
816   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1924
815   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1129
814   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1494
813   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1162
812   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1602
811   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1665
810   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1187
809   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1068
808   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1472

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN